Genmab A/S Share Price

Equities

GMAB

DK0010272202

Biotechnology & Medical Research

Market Closed - Nasdaq Copenhagen 15:59:40 22/04/2024 BST 5-day change 1st Jan Change
2,030 DKK +1.20% Intraday chart for Genmab A/S -1.36% -5.80%

Financials

Sales 2024 * 19.68B 2.81B 227B Sales 2025 * 23.49B 3.36B 271B Capitalization 130B 18.64B 1,505B
Net income 2024 * 5.11B 730M 58.94B Net income 2025 * 6.76B 966M 78B EV / Sales 2024 * 5.24 x
Net cash position 2024 * 27.32B 3.9B 315B Net cash position 2025 * 34.49B 4.93B 398B EV / Sales 2025 * 4.08 x
P/E ratio 2024 *
25.5 x
P/E ratio 2025 *
19.5 x
Employees 2,204
Yield 2024 *
-
Yield 2025 *
-
Free-Float 98.87%
More Fundamentals * Assessed data
Dynamic Chart

Latest transcript on Genmab A/S

1 day+0.72%
1 week-1.99%
Current month-3.21%
1 month-3.12%
3 months+2.52%
6 months-2.70%
Current year-6.40%
More quotes
1 week
1 960.50
Extreme 1960.5
2 089.00
1 month
1 960.50
Extreme 1960.5
2 137.00
Current year
1 825.00
Extreme 1825
2 227.00
1 year
1 825.00
Extreme 1825
2 939.00
3 years
1 825.00
Extreme 1825
3 327.00
5 years
1 075.50
Extreme 1075.5
3 327.00
10 years
180.10
Extreme 180.1
3 327.00
More quotes
Managers TitleAgeSince
Chief Executive Officer 63 31/12/98
Director of Finance/CFO 46 31/12/06
Chief Operating Officer 53 22/03/20
Members of the board TitleAgeSince
Chairman 63 31/12/16
Director/Board Member 73 31/10/03
Director/Board Member 63 31/12/15
More insiders
Date Price Change Volume
22/04/24 2,030 +1.20% 108 395
19/04/24 2,006 +0.58% 94,388
18/04/24 1,994 -0.62% 94,295
17/04/24 2,007 -2.48% 114,947
16/04/24 2,058 0.00% 138,740

Delayed Quote Nasdaq Copenhagen, April 22, 2024 at 08:31 am

More quotes
Genmab A/S specializes in the research and development of human and therapeutic antibodies intended for treating cancers, infectious diseases, rheumatoid arthritis, etc. Net sales break down by type of income as follows: - royalties (83.2%); - income from research and development (12.4%); - other (4.4%): primarily income from partnership agreement. At the end of 2023, the group had a portfolio of more than 20 products in clinical development phase and 20 in preclinical development phase. Denmark accounts for all net sales.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
A-
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
24
Last Close Price
2,006 DKK
Average target price
2,434 DKK
Spread / Average Target
+21.34%
Consensus